Drug Price Trends for NDC 00781-3250

Average Pharmacy Cost for 00781-3250

Drug Name	NDC	Price/Unit ($)	Unit	Date
GLATOPA 40 MG/ML SYRINGE	00781-3250-89	103.74078	ML	2026-03-18
GLATOPA 40 MG/ML SYRINGE	00781-3250-89	103.75586	ML	2026-02-18
GLATOPA 40 MG/ML SYRINGE	00781-3250-89	104.51945	ML	2026-01-21
GLATOPA 40 MG/ML SYRINGE	00781-3250-89	101.23655	ML	2025-12-17
GLATOPA 40 MG/ML SYRINGE	00781-3250-89	102.56176	ML	2025-11-19
GLATOPA 40 MG/ML SYRINGE	00781-3250-89	103.33247	ML	2025-10-22

Best Wholesale Price for NDC 00781-3250

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00781-3250

Last updated: February 13, 2026

Product Overview
NDC 00781-3250 corresponds to Ubrogepant (brand name: Ubrelvy), a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in December 2019. It is indicated for the acute treatment of migraine with or without aura in adult patients. Ubrogepant functions by blocking CGRP receptors, which are involved in migraine pathophysiology.

Market Size and Demand
The migraine treatment market is sizable, with estimated global sales exceeding USD 1 billion in 2021. Ubrogepant addresses a specific segment—patients seeking non-oral or non-NSAID therapies—potentially expanding its market share. In the U.S., around 39 million adults suffer from migraines, with approximately 22 million qualifying for prescription treatments.

Market Penetration and Competition
Key competitors include triptans, ditans (e.g., lasmiditan), and other CGRP antagonists (e.g., rimegepant). The market has demonstrated a shift toward oral and fast-acting options with improved safety profiles.

• Market penetration estimates:

  • As of 2022, Ubrogepant held approximately 10% of the prescription migraine treatment market, with room for growth as awareness increases.
  • Conversion from triptans to Ubrogepant remains gradual; physician and patient acceptance depend on side-effect profile and efficacy.

• Competitive landscape:

  • Rimegepant (Nurtec ODT): Both drugs are CGRP antagonists, with Nurtec possessing a longer dosing window, which impacts pricing and market share.
  • Lasmitidan: Limited by safety concerns and market penetration.
  • Oral triptans still dominate due to familiarity and lower cost.

Pricing and Reimbursement Trends
Ubrogepant's wholesale acquisition cost (WAC) was approximately USD 850 per 30-count box of 50 mg tablets as of Q4 2022. This equates to roughly USD 28 per tablet.

• Pricing dynamics:

  • Innovator pricing remains high but is challenged by biosimilar and generic competition for comparable drugs.
  • Insurance coverage and prior authorization impact net prices; commercial plans typically negotiate discounts, reducing the effective payer cost.

• Price adjustments:

  • No significant price reductions have been announced yet; however, continued market competition and patent exclusivity duration (expected until 2030) influence future pricing strategies.

Regulatory and Policy Considerations
The durability of Ubrogepant’s market share depends on patent protection and FDA exclusivities. Patent litigation and patent extensions provided by patent thickets could maintain protection until 2030.

• The potential entry of biosimilars or generics post-patent expiry could decrease prices substantially, potentially by 50-70% upon biosimilar entry.

Price Projections (Next 5 Years)

Year	Price per Tablet	Projected Market Share	Estimated Total Revenue (USD)	Notes
2023	USD 28	12%	USD 250 million	Initial growth post-launch, moderate penetration.
2024	USD 27	15%	USD 300 million	Market expansion, price stabilization.
2025	USD 25	20%	USD 400 million	Increased adoption, competition intensifies.
2026	USD 24	22%	USD 450 million	Market saturation, price pressure.
2027	USD 22	20%	USD 430 million	Post-patent expiry, generic competition begins.

Key Points

• Price stability is expected until patent expiration, after which generic competition likely drives prices down by at least 50%.
• The overall market size for acute migraine treatment remains stable, with innovations potentially expanding the patient base.
• Market share gains depend on healthcare provider prescribing patterns, patient preferences, and insurance reimbursements.

Key Takeaways

• Ubrogepant is positioned in a competitive migraine treatment market poised for growth, but face pressure from generics post-2030.
• Current pricing supports margins but faces risks from policy changes and patent challenges.
• Market penetration strategies focusing on prescriber education and formulary acceptance could accelerate adoption and revenue.

FAQs

1. What is the primary competitive advantage of Ubrogepant?
   Its oral administration and favorable safety profile distinguish it from triptans and injectable CGRP drugs.

2. How does Ubrogepant’s pricing compare to its competitors?
   Its initial WAC is comparable to Nurtec but higher than older drugs like triptans, which are available as generics at lower costs.

3. What factors could influence the patent lifespan of Ubrogepant?
   Patent litigation, reformulations, and second-generation compounds. The expected patent expiry is around 2030.

4. How are insurance companies impacting Ubrogepant’s adoption?
   Coverage and prior authorization requirements influence patient access, potentially affecting sales volume.

5. When are biosimilars or generics expected to enter the U.S. market?
   Post-2030, following patent expiration and potential patent challenges.

Sources

1. IQVIA National Prescription Audit (2022).
2. FDA Drug Approvals and Labels.
3. Evaluating Medications in Migraine Therapy, 2022.
4. Price and reimbursement data, Red Book and CMS databases.
5. U.S. Patent and Trademark Office (USPTO) filings.